President Donald Trump didn't wait long in his second term to begin shaking things up in Washington, D.C. In less than two ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

A provision about insulin in the Inflation Reduction Act is conflated with a 2022 executive order by former President Joe ...

The Inflation Reduction Act (IRA) of 2022 brought substantial modifications to the Medicare program, which are still reflected in 2025. One of these changes was a new limit for ded ...

The cap is part of the Inflation Reduction Act, the 2022 federal climate and health care bill that also empowered Medicare to negotiate drug prices with pharmaceutical companies. Because the cap ...

Under legislation passed in 2022 called the Inflation Reduction Act, Medicare was allowed for the first time to negotiate prices with drug companies on a limited number of medications.

The Inflation Reduction Act of 2022 has triggered a raft of changes to Medicare Part D plans and Medicare Advantage plans that affect prescription drug coverage in 2025. Here’s what to know.

The Biden administration, in its last full weekday in office, announced the next 15 drugs up for Medicare price negotiation. Blockbuster diabetes drug Ozempic is on the list. That means the ...

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price negotiations, federal health officials announced Friday. The negotiations for ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...